

Appl. No. 10/087,473 (Docket 090/003)
Amndt. dated Nov. 17, 2005
Reply to Office Action of July 5, 2005

Amendments to the Specification:

Please replace paragraph beginning on page 18, line 38 and ending on page 19, line 7 with the following amended paragraph:

Certain tissue-specific markers listed in this disclosure or known in the art can be detected by immunological techniques — such as flow immunocytochemistry for cell-surface markers, immunohistochemistry (for example, of fixed cells or tissue sections) for intracellular or cell-surface markers, Western blot analysis of cellular extracts, and enzyme-linked immunoassay, for cellular extracts or products secreted into the medium. The expression of tissue-specific gene products can also be detected at the mRNA level by Northern blot analysis, dot-blot hybridization analysis, or by reverse transcriptase initiated polymerase chain reaction (RT-PCR) using sequence-specific primers in standard amplification methods. Sequence data for the particular markers listed in this disclosure can be obtained from public databases such as GenBank ([URL www.ncbi.nlm.nih.gov:80/entrez](http://www.ncbi.nlm.nih.gov:80/entrez)). Expression of tissue-specific markers as detected at the protein or mRNA level is considered positive if the level is at least 2-fold, and preferably more than 10- or 50-fold above that of a control cell, such as an undifferentiated pPS cell, a fibroblast, or other unrelated cell type.